Beigene issued approximately 1.6867 million shares of restricted stock units due to vesting of ownership.
Beigene (06160) announced that on June 17, 2024, approximately 1.6867 million shares were issued due to the attribution of restricted stock units granted under the equity plan (except for company directors).
Beigene (06160.HK) received 1,686,700 restricted stock units.
Beigene (06160.HK) issued 1.6867 million common shares on June 17, 2024, due to the ownership of restricted share units granted under the equity incentive plan (excluding company directors).
Beigene (06160) issued approximately 1.6867 million shares due to restricted share units being awarded to the beneficiary.
Beigene (06160) announced on June 17, 2024 that approximately 1.6867 million shares were issued due to the allocation of restricted share units under the equity incentive plan, excluding company directors.
Beigene (06160) issued approximately 7.1742 million shares due to the allocation of restricted share units under the equity plan.
Beigene (06160) announced that a total of approximately 7.1742 million shares were issued on June 15th and 16th, 2024 due to the attribution of restricted share units granted under the equity incentive plan.
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma
BeiGene (BGNE) said Friday that preliminary data from a phase 3 study of Brukinsa in combination with venetoclax to treat patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma s
Express News | Beigene: Safety Profile Was Consistent With Results of Prior Brukinsa Studies
Express News | Beigene: Preliminary Data Suggest Promising Efficacy and Tolerability
Express News | Beigene: To Present New Data From Sequoia Study Evaluating Brukinsa® Plus Venetoclax in High-Risk First-Line Cll/Sll
BeiGene to Present New Data From SEQUOIA Study Evaluating BRUKINSA Plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
DUBAI, United Arab Emirates--(BUSINESS WIRE)--$BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclud
BeiGene, Ltd. (NASDAQ:BGNE) Shares Could Be 47% Below Their Intrinsic Value Estimate
Benign Growth For BeiGene, Ltd. (NASDAQ:BGNE) Underpins Its Share Price
BeiGene, Ltd.'s (NASDAQ:BGNE) price-to-sales (or "P/S") ratio of 6.4x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies
HK stock market anomaly | Beigene (06160) rose nearly 8% in early trading. Beigene's Her2 bispecific antibody has received market approval application acceptance.
Beigene (06160) rose nearly 8% in early trading. As of press time, it rose 6.73%, closing at HKD 99.05 with a turnover of HKD 94.1153 million.
Beigene's shares rose more than 7%. The company granted share purchase rights, restricted share units, and performance share units.
On June 13th, Beigene's ($06160.HK$) stock rose more than 7%, and at the time of publication, it rose 7.65% to HKD 99.9, with a turnover of HKD 77.3927 million. According to Futubull news, Beigene announced that on June 5, 2024, the board of directors, the remuneration committee, and/or the CEO, in accordance with the authorization, granted a total of 607,000 American depositary shares of Beigene's stock options that can be subscribed to by 264 grantees (including directors) under the 2016 equity incentive plan and granted a total of 2.8867 million stock options involving 8,745 grantees (including directors).
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Maintains Target Price $180
BofA Securities analyst David Li maintains $BeiGene(BGNE.US)$ with a hold rating, and maintains the target price at $180.According to TipRanks data, the analyst has a success rate of 17.1% and a total
Beigene Issues Shares Under Incentive Schemes
Beigene (HKG:6160) granted several share options, restricted share units, and performance share units under the 2016 Share Option and Incentive Plan, according to a Wednesday filing on the Hong Kong b
Beigene: Grants stock options, restricted stock units and performance share units.
Beigene (06160) announced that on June 5, 2024, the board of directors, compensation committee and/or the CEO, authorized according to the terms of the 2016 options and incentive plan, granted a total of 607,000 American depositary shares of stock purchase rights to 264 grantees (including directors), granted restricted share units involving a total of 2.8867 million American depositary shares of stock to 8,745 grantees (including directors), and granted performance share units involving a total of 176,000 American depositary shares of stock to 31 grantees (including one director). The company plans to act in accordance with the 2016 plan.
Beigene (06160.HK): granted stock options, restricted share units, and performance share units.
On June 12, Gelonhui announced that on June 5, 2024, the board of directors, compensation committee, and/or CEO authorized by the 2016 Options and Incentive Plan granted a total of 607,000 American Depository Shares to 264 grantees (including directors) who could subscribe to the shares, granted 2,886,700 restricted stock units (RSUs) involving 288.67 million American Depository Shares to 8,745 grantees (including directors), and granted 176,000 American Depository Shares involving performance to 31 grantees (including one director).
Express News | Zymeworks Inc: Zymeworks Is Entitled to Receive an $8 Mln Milestone Payment From Beigene
Beigene issued 77,500 shares due to the restricted share units being vested.
Beigene (06160) announced that on June 5, 2024, 77,500 ordinary shares were issued due to the attribution of restricted share units granted to the company's director under the equity incentive plan.
No Data